ArticleLiver cancer2021
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma.
Article in Liver cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Review
- Sequential Use of Systemic Therapy With Locoregional Therapy for Hepatocellular Carcinoma in Japan: Analyses of Real-World Data Based on a Health Claims Database.Cancer medicine · 2026Article
- Current Perspectives on the Use of Adjuvant Pembrolizumab for Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Review
- Immune checkpoint biology in hepatocellular carcinoma (Review).Oncology letters · 2025Review
- Comparison of outcomes between preoperative and postoperative systemic treatment in patients with hepatocellular carcinoma: a SEER database-based study.Frontiers in oncology · 2024Article
- Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan.Liver cancer · 2023Article
- Clinico-histological and molecular features of hepatocellular carcinoma from nonalcoholic fatty liver disease.Cancer science · 2023Review
- Advancing prognostic precision in hepatocellular carcinoma: a paradigm shift towards machine learning.Hepatobiliary surgery and nutrition · 2023Article
- All Stages of Hepatocellular Carcinoma Patients Benefit from Systemic Therapy Combined with Locoregional Therapy.Liver cancer · 2023Article
- Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data.Cancers · 2023Review
- Efficacy of Αtezolizumab-Βevacizumab in BCLC-C cirrhotic patients with hepatocellular carcinoma according to the type of disease progression, the type of BCLC-C and liver disease severity.Journal of cancer research and clinical oncology · 2023Article
- Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma.Liver cancer · 2023Article
- Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma.Hepatobiliary surgery and nutrition · 2023Article
- Review
- Review
- Surgical Strategies for Recurrent Hepatocellular Carcinoma after Resection: A Review of Current Evidence.Cancers · 2023Review
- Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.Oncoimmunology · 2023Review
- Article
- A six-miRNA signature as a novel biomarker for improving prediction of prognosis and patterns of immune infiltration in hepatocellular carcinoma.American journal of translational research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.